Ocugen’s COVID-19 co-vaccine development partner, Bharat Biotech, shares Phase 3 COVAXIN interim results, shows 81% efficiency Nasdaq: OCGN
European Commission designates Ocugen orphan drug products for candidates for gene therapy products, OCU400, for the treatment of Retinitis Pigmentosa as well as Liver congenital amaurosis
